Officer sold ~$1.84M of Corcept Therapeutics
Scheduled in advanceLoading…
CORT · NASDAQ · Pharmaceuticals
Pharmaceuticals company based in Redwood City, California.
In the last 90 days, no insider of Corcept Therapeutics reported an open-market purchase and 66 open-market sales worth about $59.1M. Every figure links to its official SEC, House, Senate or USAspending record.
Last closeLast close, Oct 5, 2026
$122.03
Last 12 months
Not enough history
Market value
$13.2B
Revenue
$256M
+31.7% vs the same quarter a year earlier
Free cash flow, last 12 months
$107M
This quarter $31M, a year earlier $44.2M
Net debt
—
Debt —, cash $111M, at Jun 30, 2026
Net income, last 12 months
$55.2M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Jul 29, 2026.
Insiders buying, last 90 days
None
No open-market purchases reported
Insiders selling, last 90 days
66 sales
$59.1M sold. Insiders sell for many reasons.
New federal contracts, 12 months
None
Nothing found for this company
Revenue, fiscal 2025
$761M
+12.8% vs the year before
Net income, fiscal 2025
$99.7M
As reported in the annual filing
Shares outstanding
108M
As of Jul 22, 2026
In fiscal 2025 the company spent $173M buying back its own shares. Cash actually paid, from its cash-flow statement.
Officer sold ~$1.84M of Corcept Therapeutics
Scheduled in advanceOfficer sold ~$1.02M of Corcept Therapeutics
Scheduled in advanceOfficer sold ~$600K of Corcept Therapeutics
Scheduled in advanceOfficer sold ~$514K of Corcept Therapeutics
Scheduled in advancePrices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
1 active phase 3 trial and 5 active phase 2 trials led by this company, mostly in ovarian neoplasm, ovarian cancer, neoplasms. The ones with the nearest registered primary completion date still ahead:
3 trials have a registered primary completion date that has already passed. That usually means the data are being analysed, or the entry has not been updated.
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
Last 12 months, adjusted daily closes
Adjusted close went from $89.85 on Oct 6, 2025 to $122.03 on Oct 5, 2026 (+35.8%). Disclosed activity in the last 12 months: 2 insider purchases, 110 insider sales (105 under pre-arranged plans), 0 Congress purchases, 0 Congress sales.
Top officer leaving
“On September 22, 2026, Sean Maduck, the President of Corcept Endocrinology, notified the Board of Directors of Corcept Therapeutics Incorporated (the “Company”) of his decision to resign effective as of October 1, 2026.”
9 insiders sold ~$47.8M in the 60 days before
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.